Journal
CURRENT OPINION IN CHEMICAL BIOLOGY
Volume 12, Issue 1, Pages 72-77Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.cbpa.2008.02.010
Keywords
-
Categories
Ask authors/readers for more resources
Availability of a suite of biomarkers; for early detection, stratification into distinct subtypes, and monitoring progression or response to therapy promises significant improvements in clinical outcomes for cancer patients. However, despite the recent progress in proteomics technologies based on mass spectrometry (MS), discovery of novel clinical assessment tools has been slow. This is, partly due to the inherent difficulties in working with blood as the biospecimen for candidate discovery. A better understanding of the limitations of blood for comparative protein profiling and a better appreciation of the advantages of cancer tissue or cancer cell secretomes have the potential to greatly enhance the progress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available